Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with non-small cell lung cancer. Its preclinical products include CLN-049, a humanized bispecific antibody for the treatment of acute myeloid leukemia; CLN-619, a monoclonal antibody for the treatment of solid tumors; CLN-617, a fusion protein for the treatment of solid tumors; CLN-978, a T cell engaging antibody for B-cell malignancies; Opal, a bispecific fusion protein to block the PD-1 axis, and to activate the 4-IBB/CD137 pathway on T cells in tumors; and Jade, a cell therapy to target a novel senescence and cancer-related protein. The company has collaboration agreements with Cullinan Pearl Corp. to develop, manufacture, and commercialize CLN-081 and products containing CLN-081; and Adimab, LLC to discover and/or optimize antibodies. Cullinan Oncology, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

Cullinan Oncology, Inc.

Cullinan Oncology is dedicated to creating new standards of care for patients with cancer.

We innovate without borders to find the most promising clinic-ready cancer therapies, whether from our own discovery efforts or through exceptional engagement with our academic and industry partners.

Anchored in a deep understanding of immuno-oncology and translational cancer medicine, we leverage our scientific excellence in small molecules and biologics to create differentiated ideas, identify unique targets, and select the optimal modality to develop transformative therapeutics across cancer indications.

Cullinan Pearl

Biotechnology Value Fund

BVF Partners

MPM Capital

Schooner Capital

Venrock Healthcare Capital Partners

Nextech Invest

OrbiMed

Cowen Healthcare Investments

Eventide

F2 Ventures

Foresite Capital

Cullinan Oncology

CLN-617 is a potential first-in-class cytokine therapy for intratumoral injection, uniquely combining IL-2 and IL-12 in a single molecule. 
 
Preclinical studies show CLN-617 can also significantly impact the growth of non-injected tumors. That in combination with checkpoint inhibitors helps to completely eradicate distant tumors. Currently, this molecule is being evaluated in a phase 1 clinical trial. Learn more: https://bit.ly/43XVCG1 

Nadim Ahmed, President & CEO, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Thursday, January 11 at 10:30 a.m. PST. A live webcast of the presentation will be available on the “Events and Presentations” section of our website. https://bit.ly/3v5Zuc0 

#JPM24 #JPM2024

Today, we announced the first patient has been dosed in a Phase 1 clinical trial of CLN-617, a potential first-in-class cytokine therapy comprised of two potent and synergistic antitumor cytokines, IL-2 and IL-12, in a single molecule. Learn more:  https://bit.ly/47Xk1y6

We prioritize creating robust clinical programs to advance our diversified pipeline. Our approach ensures we can successfully:  
 
⚬ Move our assets through development with strong expertise and collaboration 
⚬ Garner real-time data to inform smart clinical decision-making 
⚬ Better understand assets’ potential and whether programs can be best used in combination with other agents 
 
Learn more about our R&D process: https://bit.ly/41nhlWQ  

NASDAQ:CGEM

Cullinan Oncology

Last Close

27.01

01/05 20:00

Market Cap

559.14M

Beta: 0.10

Volume Today

1.28M

Avg: 224.28K

PE Ratio

−4.92

PFCF: −5.42

Filings Not Available

Please Sign In To Use The Chat